Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation

• US 20090012157A1
• Filed: 02/06/2007
• Published: 01/08/2009
• Est. Priority Date: 02/06/2006
• Status: Abandoned Application

• Current Assignee: Barry D. Sears
• Original Assignee: Barry D. Sears
• Inventors: Sears, Barry D.
• Application Number:
  US12/278,226
• Publication Number:
  US 20090012157A1
• Time in Patent Office: Days
• US Class Current: 514/464
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/357 having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• CPC Class Codes: A61K 31/36 Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• CPC Class Codes: A61K 31/75 of ethene
• CPC Class Codes: A61K 31/77 of oxiranes
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a novel class of inhibitor of arachidonic acid useful for treating inflammatory conditions. Specifically, the invention relates to hydrophobic and hydrophilic derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.

Claims

1. A method for inhibiting the formation of arachidonic acid in a mammal comprising administering to a mammal a composition comprising a non-toxic derivative of sesamol.

2. The method of claim 1 wherein the non-toxic derivative comprises at least one fatty acid.

3. The method of claim 2 wherein the at least one fatty acid comprises 2 to 22 carbon atoms.

4. The method of claim 2 wherein the degree of unsaturation of the at least one fatty acid ranges from 0 to 6.

5. The method of claim 2 wherein the at least one fatty acid is selected from the group consisting of palmitic acid, oleic acid, linoleic acid, alpha-linolenic acid, arachidic acid, gadoleic acid, 5,8,11,14,17-eicosapentaenoic acid, and 4,7,10,13,16,19-docosahexaenoic acid.

6. The method of claim 2 wherein the non-toxic derivative comprises sesamol oleate.

7. The method of claim 1 wherein the non-toxic derivative comprises a carboxylic acid derivative of polyethylene oxide.

8. The method of claim 7 wherein the carboxylic acid derivative of polyethylene oxide comprises 2 to 400 repeating units.

9. The method of claim 1 wherein the composition is prepared as a nutritional supplement in a form selected from the group consisting of a capsule, a bar, a tablet, a powder, and a beverage package.

10. A method for moderating an inflammatory response in a mammal comprising administering to a mammal a composition comprising a non-toxic derivative of sesamol.

11. The method of claim 10 wherein the administering step is carried out enternally or parenternally.

12. The method of claim 10 wherein the composition is prepared as a nutritional supplement in a form selected from the group consisting of a capsule, a bar, a tablet, a powder, and a beverage package.